Full Video Transcript
Although the Food and Drug Administration approved Xarelto for preventing pulmonary embolisms in joint replacement recipients, there are serious warnings of which to take note. First, the FDA delayed approval of Xarelto for two years with concerns that the drug causes potentially fatal internal bleeding. In addition, the FDA issued its most serious warnings known as "black box" warnings, advising patients and physicians that epidural or spinal hematomas in particular can be dangerous when patients receive neuraxial anesthesia or undergo spinal procedures while taking Xarelto. Epidural and spinal hematomas can cause paralysis. When concerned about these warnings consult with your doctor.